Recap: Ironwood Pharmaceuticals Q1 Earnings

Shares of Ironwood Pharmaceuticals IRWD remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share were up 500.00% over the past year to $0.24, which beat the estimate of $0.21.

Revenue of $88,845,000 higher by 11.14% from the same period last year, which missed the estimate of $95,200,000.

Looking Ahead

The upcoming fiscal year's revenue expected to be between $370,000,000 and $385,000,000.

Conference Call Details

Date: May 06, 2021

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.ironwoodpharma.com%2F&eventid=3082418&sessionid=1&key=851F8750615C94C37C91C4699B9A715B&regTag=&V2=false&sourcepage=register

Price Action

Company's 52-week high was at $12.55

52-week low: $8.63

Price action over last quarter: Up 16.20%

Company Description

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.